jueves, 10 de marzo de 2011

Premastication of Food by Caregivers of HIV-Exposed Children --- Nine U.S. Sites, 2009--2010

Estimados colegas, les dejo otra noticia sobre VIH.
Saludos
Dr. Carlos Erazo

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6009a2.htm?s_cid=mm6009a2_e&source=govdelivery

Weekly

March 11, 2011 / 60(09);273-275


Premastication (i.e., chewing foods or medicines before feeding to a child) was reported recently as a route of human immunodeficiency (HIV) transmission through blood in saliva (1) and has been associated with transmission of other pathogens (2--7). Approximately 14% of caregivers in the United States report premastication (8); however, the frequency of this behavior among HIV-infected caregivers is unknown. To assess the prevalence of premastication among caregivers of children being treated in pediatric HIV clinics, which include perinatally HIV-exposed children (i.e., HIV-uninfected and HIV-infected children born to an HIV-infected mother), CDC conducted a cross-sectional survey at nine such clinics in the United States during December 2009--February 2010. This report describes the results of that survey, which indicated that among primary caregivers of children aged ≥6 months, 48 (31%) of 154 reported the children received premasticated food from themselves or someone else. Approximately 37% of black caregivers reported premastication, compared with 20% of non-black caregivers (prevalence ratio [PR] = 1.8). Premastication decreased with caregiver age and was used to feed children aged 1--36 months. Public health officials and health-care providers should educate the public about the risk for disease transmission via premastication and advise HIV-infected caregivers against the practice.
Pediatric HIV clinics with which the CDC had collaborated previously in premastication-related or longitudinal, HIV-related epidemiologic studies participated in this investigation. These clinics were located in Atlanta, Georgia; Dallas, Texas; Houston, Texas; Memphis, Tennessee; Miami, Florida; New Orleans, Louisiana; Newark, New Jersey; San Juan, Puerto Rico; and the District of Columbia. A 10-minute, self-administered paper questionnaire was distributed to primary caregivers during their child's clinic visit. A primary caregiver was defined as the person responsible for feeding, clothing, and housing the child. One survey per child with an appointment was allowed; therefore, multiple interviews were possible if a caregiver had multiple children with appointments. After completion of the survey, caregivers were provided written information and counseled about the risk for disease transmission through premastication. Of 203 primary caregivers approached, 192 (95%) were surveyed (11 declined participation).
Of the 192 primary caregivers surveyed, the majority were biologic mothers of the children (81%) and U.S.-born (86%). Approximately 66% of caregivers were non-Hispanic black, 24% were Hispanic, and 7% were non-Hispanic white. The median age was 31 years for primary caregivers (range: 15--77 years) and 2 years for children (range: <1--18 years). Approximately 30% of caregivers had less than a high school education, and 49% had an annual household income of less than $12,000.
Given the decreased likelihood that children are fed solid foods during the first months of life, CDC limited its analysis to caregivers of children who were aged ≥6 months at the time of investigation (155 [81%] of 192). Among primary caregivers of these children, 44 (29%) of 153 reported ever premasticating food for the child. Fourteen (10%) of 140 primary caregivers reported that someone else had given premasticated food to the child. Overall, 48 (31%) of 154 primary caregivers stated that they or someone else had premasticated food for the child, with biologic mothers representing 79% of premasticators. Black caregivers more frequently reported ever premasticating food, compared with non-blacks (37% versus 20%, respectively; PR = 1.8) (Table 1). Premastication decreased with increasing caregiver age at interview. Caregivers aged ≤19 years were significantly more likely to premasticate than those aged ≥40 years (44% versus 13%, respectively; PR = 3.5), as were those aged 20--29 years (38% versus 13%, respectively; PR = 2.9) and those aged 30--39 years (36% versus 13%, respectively; PR = 2.8). Similar prevalences of premastication were found regardless of the sex of the child and the primary caregiver's country of origin, education level, and income (Table 1).
Primary caregivers started premastication of food for children as young as age 1 month (median age: 7 months) and stopped premastication as late as age 36 months (median age: 13 months). Among 38 premasticating primary caregivers who described frequency of the behavior, 15 (39%) reported premasticating 1--3 days in a typical week, 14 (36%) reported 4 or more days, and nine (24%) reported less than once a week. The most commonly reported reasons for premastication, reported from a predetermined list, were "child wanting some of the caregiver's food" (64%), "caregiver not wanting the child to choke" (62%), and "prechewing is done in my family" (31%) (Table 2). Meat and fish (80%) and fruit (39%) were the most commonly reported food types premasticated by caregivers.

Reported by

N Rakhmanina, MD, Children's National Medical Center; S Hader, MD, A Denson, Dept of Health, Washington, DC. A Gaur, MD, St. Jude Children's Research Hospital, Memphis, Tennessee. C Mitchell, MD, Miller School of Medicine, Univ of Miami. S Henderson, MD, Emory Univ, Atlanta, Georgia. M Paul, MD, Baylor College of Medicine, Texas Children's Hospital, Houston; T Barton, MD, Southwestern Medical Center, Dallas, Texas. M Herbert-Grant, MD, University Hospital, New Jersey Medical School. E Perez, Univ of Puerto Rico. J Malachowski, Tulane Univ School of Public Health, New Orleans, Louisiana. K Dominguez, MD, S Danner, S Nesheim, MD, Div of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; W Ivy, PhD, D Iuliano, PhD, EIS officers, CDC.

Editorial Note

In 2007, an estimated 13% of 159 diagnoses of HIV and acquired immunodeficiency syndrome (AIDS) among children aged <13 years were attributed to modes other than perinatal transmission, including hemophilia, blood transfusion, and risk factors not reported or identified.* In 2008, a case series of three pediatric HIV cases concluded that premastication was the likely mode of transmission for these children, a route not reported previously (1). Bleeding gums at the time of premastication were reported in caregivers of two of the three children in the case series. The third caregiver could not recall her dental condition at the time of premastication. One of these transmissions was to a child whose mother was not HIV-infected. HIV transmission via premastication is presumed to require blood in the mouth of the caregiver. No evidence suggests that saliva alone can transmit HIV.
In addition to HIV, transmission of hepatitis B virus (3) and group A streptococcus (6) by premastication has been documented. Furthermore, premastication has been found to be associated with increased risk for infection with Helicobacter pylori (7), Streptococcus mutans (2), human herpesvirus 8 (4), and Epstein Barr virus (5). Only one study has indicated that premastication can be associated with decreased risk for infection; that study involved respiratory syncytial virus in Alaska Native infants aged <6 months (9).
The prevalence of premastication observed in this investigation is particularly important because most of the caregivers and premasticators were biologic mothers; thus, most caregivers were HIV-infected, posing a potential risk for HIV transmission to children in their care who are uninfected. Furthermore, the higher prevalence of premastication among black and younger caregivers suggests the need for targeted prevention messages for these populations.
The reasons given by caregivers for premastication might suggest that the practice is mostly situational or in response to immediate circumstances, as opposed to reasons that reflect an inability to provide baby food or formula. Therefore, prevention messages might be effective among this population, particularly those with situational reasons for premastication. Qualitative research on premastication might be helpful to explore the reasons for premastication and to determine helpful, realistic alternatives for HIV-infected caregivers.
The findings in this report are subject to at least three limitations. First, gathering HIV status information on caregivers was not possible because surveys were completed in a setting where caregivers were accompanied by their children and other family members, some of whom might have been unaware of their caregiver's HIV status. However, given that all caregivers were surveyed in pediatric HIV clinics and 81% of primary caregivers were biologic mothers, the majority of the caregivers surveyed likely were HIV-infected. Second, the surveyed caregivers were asked to recall behaviors that might have taken place several years before survey administration; therefore, these data might be affected by recall bias. Finally, this cross-sectional investigation included a convenience sample of caregivers of children seen in HIV clinics and is not generalizable to all HIV-infected caregivers.
Although research on the risk for HIV transmission via premastication is limited, CDC recommends that HIV-infected caregivers not premasticate food for HIV-uninfected children because of the possibility of transmitting HIV to the child. Public health officials and health-care providers should continue to educate the public about the risk for disease transmission, including HIV, via premastication.

References

  1. Gaur AH, Dominguez KL, Kalish ML, et al. Practice of feeding premasticated food to infants: a potential risk factor for HIV transmission. Pediatrics 2009;124:658--66.
  2. Harrison R, Benton T, Everson-Stewart S, Weinstein P. Effect of motivational interviewing on rates of early childhood caries: a randomized trial. Pediatr Dent 2007;29:16--22.
  3. Huang MJ. An epidemiological study on prevalence and risk factors of hepatitis B virus (HBV) infection in preschool children [Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 1990;11:129--32.
  4. Mbulaiteye SM, Pfeiffer RM, Whitby D, Brubaker GR, Shao J, Biggar RJ. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis 2003;187:1780--5.
  5. Mbulaiteye SM, Walters M, Engels EA, et al. High levels of Epstein-Barr virus DNA in saliva and peripheral blood from Ugandan mother-child pairs. J Infect Dis 2006;193:422--6.
  6. Steinkuller JS, Chan K, Rinehouse SE. Prechewing of food by adults and streptococcal pharyngitis in infants. J Pediatr 1992;120(4 Pt 1):563--4.
  7. Taylor DN, Blaser MJ. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991;13:42--59.
  8. Fein SB, Labiner-Wolfe J, Scanlon KS, Grummer-Strawn LM. Selected complementary feeding practices and their association with maternal education. Pediatrics 2008;122(Suppl 2):S91--7.
  9. Bulkow LR, Singleton RJ, Karron RA, Harrison LH. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109:210--6.

miércoles, 9 de marzo de 2011

Guia sobre indicadores para la vigilnacia y notificacion de la respuesta del sector salud VIH/SIDA Enero 2011

Añadir leyenda

New data from PrEP study shed light on adherence, bone mineral loss and resistance

Estimados colegas les dejo esta información que la pueden encontrar en el siguiente link:

http://www.aidsmap.com/page/1682919/
 
Saludos 
Dr. Carlos Erazo
 
Gus Cairns
Published: 02 March 2011
Bob Grant, lead investigator of iPrEx. Photo by Gus Cairns/aidsmap.com
Near-perfect adherence to oral pre-exposure prophylaxis – taking HIV drugs to prevent HIV – may be achievable in the right settings, the eighteenth Conference on Retroviruses and Opportunistic Infections heard yesterday.
Participants from the US sites of the international iPrEx study of tenofovir/FTC (Truvada) pre-exposure prophylaxis (PrEP) in men who have sex with men and transsexual women had near-perfect adherence, compared with 50% adherence from other sites, new data presented at the conference shows.
Analysis also found that adherence in men who had the highest risk of acquiring HIV, by having unprotected receptive anal sex, was, at 76%, far higher than those at lower risk, so participants were tempering their pill-taking to their perceived risk.
Another substudy has found that taking Truvada resulted in a small but significant loss in bone mineral density in participants. But it also found that participants’ bone mineral density at the start of the study was considerably lower than would have been expected in men their age.
Resistance tests uncovered no drug resistance in men who seroconverted (became infected with HIV) on the trial, but did find that one participant who took placebo had a small amount of virus with the K65R resistance mutation to tenofovir.
At a discussion forum on iPrEx and on the CAPRISA 004 microbicide trial, lead investigator Bob Grant announced that the US Food and Drug Administration had agreed that the iPrEx trial findings were sufficient for the FDA to move ahead and consider changing the indication for Truvada to include using it to prevent HIV.
PrEP, as a result, might be approved in the US by the end of this year.

Updated trial results

In the paper published on the trial findings in the New England Journal of Medicine last November, data were given up to May 2010. Bob Grant presented final figures for the trial, whose last participants left the trial in August 2010.
The final tally was that 130 HIV infections were seen in the 2499 men taking part in the trial, 48 of those taking Truvada and 82 on placebo, a rate of 2.6% a year. There were also 10 infections in men who had acute HIV symptoms at the time they enrolled, two of whom appear to have acquired resistance to FTC, and six infections in the three months immediately following the trial, four of them in men who had taken Truvada.
This means that the final efficacy figure in the ‘modified intent to treat’ (MITT) analysis, which excluded the men who had HIV at the start of the study and ignores factors like adherence and sexual risk, was 42%.
Efficacy was greater in men over 25 (56%), in men who reported greater than 90% adherence (68%), and, for reasons that are unclear, in the relatively small number of men who were circumcised (76%).

Adherence

One of the surprises of the original trial was that while mean reported adherence was 95%, a study of drug levels found that only 50% of a random sample of men who did not acquire HIV had detectable drug in their white blood cells. Only 9% of those who seroconverted had any drug in their cells either. Drug can be detected in cells for several weeks and this shows, in the words of Bob Grant, that “people were either taking it daily or not at all”.
A new analysis of drug levels in 179 participants by Peter Anderson of the University of Colorado confirmed that only 50% had detectable tenofovir in their cells and 62% detectable FTC. However 97% of the 227 participants from the two sites in the USA, in San Francisco and Boston, had detectable drug, showing that adherence was near-perfect in this more treatment-literate group. It also confirmed that adherence was better in men over 25 (73%) than men under 25 (44%).
Adherence analysis also showed that participants tempered their adherence according to their level of risk; 76% of those who had had unprotected receptive anal sex in the previous twelve weeks had significant drug levels versus 36% of those who had not and 25% of those who had had no sex at all.
Rivet Amico of the University of Connecticut presented an analysis of how self-reporting and pill counts correlated with actual adherence in the study. There were four measures of adherence taken during the study: self-reports by interview and by computer-assisted interview, pill count of the number of pills dispensed minus those returned, and the medication possession ratio (MPR), which was a measure, based on refill rates, of how many pills the participants had relative to the number that would last exactly till the next visit (thus an MPR of 1.25 meant they had 25% more pills than the minimum needed).
MPR was the most accurate guide to actual adherence. Only 68% of those claiming 100% adherence by self-report were actually adherent; only 62% of those claiming 100% adherence by computer-assisted interview; and only 59% of those assessed as having 100% adherence by pill count. But 75% of those assessed as having 100% adherence by MPR actually were so. The overall ‘positive predictive value’ of a claim of 100% adherence was 69%, meaning that 31% of those assessed as having 100% adherence did not. The ‘negative predictive value’ of a claim of less than 100% adherence was 95%, however, meaning that self-reports of poor adherence could be relied on.

Bone mineral density

One concern in trials using tenofovir as post-exposure prophylaxis has been that all antiretrovirals seem to cause a transient loss in bone mineral density, but that this seems to be larger and in some studies persistent in people taking tenofovir.
A study of 2045 iPrEx participants using DEXA scans (Mulligan) found that bone mineral density (BMD) scores at trial recruitment were already lower than would have been expected in men of the same age. Twelve per cent of participants had a ‘Z score’ for BMD in their spine of more than minus two, meaning that they fell into the lowest 5% of BMD values for an average population. BMD scores in the hip were also lower than expected.
During the trial BMD declined approximately 0.6% further in the spine (though not in the hip) in people taking Truvada but did not decline in subjects taking placebo, during the first six months. In the minority of subjects so far measured out to 18 months it declined by 1%. Nine per cent of subjects on Truvada had a loss of more than 5% in their spinal BMD compared with 4% on placebo.
This 1% average decline compares with an average 2 to 4% decline in patients taking tenofovir for treatment. There appeared to be no clinical effects, but at present we only have data on most subjects for the first six months, so it is not known if this bone loss is progressive or will stabilise.
Another study of BMD was presented from a different PrEP study: the safety trial of tenofovir PrEP in 400 US gay men which ended in July 2010 (Liu). This substudy only looked at the 200 participants from San Francisco. It found a loss of about 2% BMD in the neck of the hip bone over two years, though not in the spine.
This study also found lower-than-expected BMD in study entrants. It found than men using amphetamines were six times more likely to report low BMD at baseline and users of poppers 4.5 times as likely; conversely men who took vitamin D, calcium or multivitamins were 70% less likely to report low BMD.  

References

Grant R et al. Pre-exposure chemoprophylaxis for prevention of HIV among trans-women and MSM: iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 92, 2011.
Anderson P et al. Interpreting detection rates of intracellular FTC-TP and TFV-DP: the iPrEx trial. 18th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 96LB, 2011. 
Amico R et al. Adherence indicators and PrEP drug levels in the iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 95LB, 2011.
Mulligan K et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 94LB, 2011.
Liu A et al. BMD loss in HIV men participating in a TDF PrEP clinical trial in San Francisco. 18th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 93, 2011.

Abstracts and webcasts

You can view the abstracts from this research on the official conference website:
Abstract 92: www.retroconference.org/2011/Abstracts/42567.htm
Abstract 96LB: www.retroconference.org/2011/Abstracts/42612.htm
Abstract 95LB: www.retroconference.org/2011/Abstracts/42627.htm
Abstract 94LB: www.retroconference.org/2011/Abstracts/42550.htm
Abstract 93: www.retroconference.org/2011/Abstracts/40208.htm
You can also watch a webcast of the presentations made at this conference session, including the speakers Robert Grant, Peter Anderson, Rivet Amico, Kathleen Mulligan and Albert Liu.
Webcast from Advances in PrEP.
We rely on donations to continue our work to help people with HIV, support us today at: www.aidsmap.com/donate

jueves, 3 de marzo de 2011

LA INVESTIGACION EN SALUD Y LA EDUCACION EN SALUD PUBLICA EN EL ECUADOR

Estimados colegas aqui una visiçon sobre la investiogación en el Ecuador.
Saludos 
Dr. Carlos Erazo


Dr. Mario Paredes Suárez*
Dr. Ramiro López Pulles*
*Proceso de Ciencia y Tecnología en Salud (PCYT)
Ministerio de Salud Pública del Ecuador
1. INTRODUCCION
Al hablar de la investigación científica, del Desarrollo Tecnológico y de la Innovación, debemos
partir de una perspectiva particular cuando enfrentamos este aspecto entre países
industrializados y países en desarrollo, pues si bien es verdad se presenta como una
necesidad y urgencia común, las características en cada uno de ellos, son muy diferentes.
En 1977, durante la realización de la Asamblea Mundial de la Salud, la OPS/OMS, proclamó al
mundo uno de los objetivos más importantes, de Políticas Mundiales, a fin de mejorar la calidad
de atención a la Salud y de rescatar a un número muy importante de la comunidad mundial,
que se hallaba en circunstancias deplorables en su atención médica y en sus niveles de salud y
de vida. Esta proclama, “Salud Para Todos en el Año 2000", vino a transformarse en la meta
más ansiada por los países de mundo, en especial de aquellos pequeños, de economías
precarias, altamente dependientes y con índices alarmantes de salud.
En 1978, en Alma Ata, la misma OPS/OMS, con el objeto de operacionalizar el postulado
anterior, propuso la estrategia de “Atención Primaria" para facilitar la ejecución de programas
mínimos de atención y tratar de cubrir el enorme déficit que existía en ese entonces.
Posteriormente, en 1981, esta misma organización adoptó el Plan Para Latinoamérica, que
tenía por objetivo desarrollar y promocionar actividades en salud en los países en desarrollo y
que podría contribuir a alcanzar los objetivos de las propuestas anteriores. Uno de los
componentes más importantes de este Plan fue el relacionado con la Investigación Biomédica.
En el Ecuador, en el período 2001 y 2002 se establece la Política y la Ley del Sistema Nacional
de Salud, que marcaron tanto los principios generales como los aspectos jurídicos a la reforma
estructural del sector de la salud. Otro hecho constituye el inicio de actividades encaminadas a
la participación de los diferentes integrantes del Sistema Nacional de Salud y de la sociedad
civil que promovieron, en octubre del 2002, el Foro Nacional de Investigación en Salud y para
marzo del 2004, se instala la Comisión de Ciencia y Tecnología (COMCYT) del Consejo
Nacional de Salud (CONASA), con funciones específicas detalladas en el Reglamento a la Ley,
e integrada por todos los delegados de las instituciones que constituyen el Sistema Nacional de
Salud.
En cumplimiento de la legislación vigente en el Ecuador, el Ministerio de Salud Pública lidera la
Investigación y el Desarrollo Tecnológico en Salud, a través del Proceso de Ciencia y
Tecnología (PCYT); quien por expreso mandato y, a través de su Misión y Visión, debe normar,
organizar y controlar la Investigación en Salud, el Desarrollo Tecnológico del sector y la
aplicación de la Bioética en las actividades relacionadas.
Los soportes legales emanados de la Política Nacional de Ciencia y Tecnología del
FUNDACYT/SENACYT, la formulación de la Política Nacional de Investigación en Salud y los
Acuerdos respectivos acreditan estas atribuciones a este Proceso (PCYT).
No debemos olvidar que, la globalización ha rebasado los límites de la geoeconomía y la
geopolítica para introducirse en el pensamiento científico y, por ello, debemos adelantarnos a
los acontecimientos futuros y desarrollar acciones que destaquen la importancia de las alianzas
estratégicas con todos los sectores involucrados en el avance de la investigación, la ciencia y
la tecnología en salud.
Las actividades de la investigación, la ciencia y la tecnología no deben concentrarse a
proyectos de corto plazo. Debemos mirar con perspectiva lo que el conocimiento nos pone en
nuestras manos y, acorde a esta perspectiva, elaborar, proponer y desarrollar protocolos y
propuestas de mediano y largo plazo definiendo algunos elementos detonadores de esta visión,
asegurando que sus beneficios contribuirán a mejorar la calidad de vida y de salud de los
ecuatorianos.
En soporte a estos conceptos, el modelo de acción del Ministerio de Salud Pública en el campo
de la investigación en salud se enmarca en las recomendaciones de la OPS/OMS así como en
el cumplimiento de los objetivos y metas del Milenio, como compromiso universal.

Salud del adolescente / Cursos gratuitos

Dear Colleague:
We are pleased to present the third CDC Learning Connection Spotlight for 2011: Teen Heath at http://www.cdc.gov/learning/spotlight.html. This Spotlight provides learning products and resources to better prepare the public health community to promote safe and nurturing environments for teens to become healthy, productive adults.
Learning products featured in the Spotlight include the following:
Dating Matters: Understanding Teen Dating Violence Prevention
  • Designed to help educators, youth-serving organizations, and others working with teens understand the risk factors and warning signs associated with teen dating violence
  • Developed by the Centers for Disease Control and Prevention (CDC) in partnership with Liz Claiborne, Inc.
  • Provides an interactive resource center with access to additional dating violence information, links to curricula, strategies, and tools
Using Evidence for Public Health Decision Making: Violence Prevention Focused on Children and Youth
  • Summarizes the findings of the Task Force on Community Preventive Services
  • Reviews the effectiveness of violence prevention interventions focused on children and youth
Teen Health resources include
Share the Spotlight.
Teen Health eCard Thumbnail 
Send a CDC Learning Connection Health-e-Card.

Through the CDC Learning Connection, you can 
  • Access over 200 products in this growing collection of public health-related learning
  • Find e-learning, podcasts, electronic publications, webcasts, and more
  • Locate courses that offer continuing education (CE) credits
  • Access featured e-learning that meet specific selection criteria
If you have any questions or comments, please contact learning@cdc.gov.

 
 

To receive the latest news for your region, please update your profile with your country, state and zip code.
Questions or problems? Please contact support@govdelivery.com.
Dept of Health and Human Services Logo




CDC Logo
 

miércoles, 2 de marzo de 2011

HCV Infection in HIV-Positive MSM

In HIV-positive men who have sex with men, HCV acquisition is not uncommon and is often due to sexual exposure.
Sexual transmission of hepatitis C virus (HCV) has been thought to be relatively inefficient. Furthermore, in cases of HIV/HCV coinfection, HCV infection has been thought to typically precede HIV infection. However, these views were challenged after outbreaks of acute HCV infection were documented among HIV-positive men who have sex with men (MSM). Now, two studies show that new HCV infections in HIV-positive MSM often seem to be acquired through sexual contact.
Taylor and colleagues determined the incidence of HCV infection in a U.S.-based cohort of HIV-positive men who had participated in various clinical trials. Of 1830 men who were initially HCV-negative, 36 subsequently seroconverted, for an overall incidence rate of 0.51 cases per 100 person-years. Seroconverters were predominantly white and often college-educated, with a mean age of 46; notably, three quarters reported no injection-drug use (IDU), implying possible sexual acquisition of HCV.
Matthews and colleagues described 163 individuals in Australia with acute HCV infection (31% HIV-positive; 72% men). Eighteen percent of the study participants likely acquired their HCV infection through sexual exposure, and most of these were HIV-positive MSM. Phylogenetic analysis of HCV sequences suggested that infections among HIV-positive MSM often originate from a potential common source — and that transmission of HCV to HIV-positive individuals occurs within social networks in which IDU and sexual risk behaviors coexist.
Comment: HCV testing in HIV-positive patients has historically been recommended only at the time of HIV diagnosis. However, the recognition that HIV-positive MSM are at risk for acquiring HCV infection has led the European AIDS Treatment Network (NEAT) to now recommend annual HCV antibody testing in high-risk HIV-positive individuals — and HCV RNA testing if acute infection is suspected. U.S. guidelines are likely to follow suit. An important reason for identifying patients with newly acquired HCV infection is the relatively high efficacy of early versus later treatment — a topic nicely summarized in the new NEAT guidelines.
Rajesh T. Gandhi, MD
Published in Journal Watch HIV/AIDS Clinical Care February 28, 2011

Citation(s):

Tayor LE et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis 2011 Jan 31; [e-pub ahead of print]. (http://dx.doi.org/10.1093/cid/ciq201)
Matthews GV et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2011 Jan 31; [e-pub ahead of print]. (http://dx.doi.org/10.1093/cid/ciq200)
The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: Recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011 Feb 20; 25:399.

Putting PrEP into Practice

A young man who repeatedly engages in high-risk sexual activity with other men requests pre-exposure prophylaxis to prevent HIV infection. Do you oblige?
A 29-year-old man goes to the emergency department (ED) to request post-exposure prophylaxis (PEP) to prevent HIV infection. He has just returned from a week-long vacation, during which he had unprotected oral and receptive anal intercourse with several men whose HIV status he does not know. His last HIV test was 6 months prior to this ED visit, and the result was negative. He reports no medical problems and is not taking any medications. He receives a 28-day course of tenofovir/FTC + lopinavir/ritonavir PEP.
Four days later, the patient has a follow-up visit with his primary care provider (PCP), who is aware that he has received at least three similar courses of PEP during the previous 4 years. His HIV antibody test has again returned negative. He says he is aware of when he is going to put himself at high risk for HIV infection (usually during vacations and particular weekends) and would like a supply of tenofovir/FTC to take during these periods; however, he does not want to take the drugs continuously.
If you were the PCP, what additional history would you obtain? Would you try to change the patient's high-risk behavior? If so, what specifically would you say to him? Would you recommend tenofovir/FTC pre-exposure prophylaxis (PrEP) for him? If so, would it be continuous or intermittent? How frequently would you monitor for HIV, other sexually transmitted infections, and tenofovir/FTC toxicity? If you would not prescribe PrEP, what is your reasoning?
Published in Journal Watch HIV/AIDS Clinical Care February 28, 2011

martes, 1 de marzo de 2011

Transmitted HIV Resistance Ups Risk of Tx Failure

Estimados colegas, les dejo esto para su información.



 
Transmitted resistance to HIV drugs sharply increases the risk that a patient's first anti-retroviral regimen will fail, researchers reported.

In an analysis of more than 10,000 treatment-naive patients, transmitted resistance to at least one drug in the first regimen increased the risk of virological failure by a factor of three, compared with patients with no resistance mutations, according to Linda Wittkop, MD, of the University Bordeaux Segalen in Bordeaux, France, and colleagues.

On the other hand, patients who had transmitted resistance but were still placed on a fully active combination therapy were not significantly less likely to fail treatment, Wittkop and colleagues reported online in The Lancet.
Action Points  
  • Explain that in a multi-cohort study of over 10,000 patients, transmitted resistance to HIV drugs sharply increases the risk that a patient's first anti-retroviral regimen will fail.
  • Note that in contrast, patients who had transmitted resistance but were still placed on a fully active combination therapy were not significantly less likely to fail treatment.
  • Note that the vast majority of the patients, 90.5%, had no transmitted resistance on baseline testing.
The finding confirms recommendations that physicians and patients should choose an initial three-drug treatment regimen after resistance testing, Wittkop and colleagues argued.
Drug resistance is a continuing problem in HIV treatment, especially in the context of poor adherence, and if the resistant strains are transmitted, they are known to make treatment difficulty, the researchers noted.
But the effect of transmitted drug resistance has not been fully quantified in large numbers of patients, they reported.
To help fill the gap, they studied outcomes of 10,056 anti-retroviral-naïve patients who started combination therapy after Jan. 1, 1998, and had at least one sample for a genotypic test taken before the start of treatment.
The good news from the so-called EuroCoord-CHAIN study was that the vast majority of the patients -- 90.5% -- had no transmitted resistance, the researchers reported. Another 4.7% had at least one resistance mutation but still got fully active therapy.
And 4.8% had at least one mutation and were resistant to at least one of the drugs they were initially given, Wittkop and colleagues reported.
For the analysis, virological failure was defined as two consecutive viral loads over 500 copies for HIV RNA per milliliter of blood after six months of treatment, with the date of the first high viral load being the date of failure.
The researchers found that the cumulative Kaplan-Meier estimates for virological failure at 12 months were:
  • 4.2% for patients without resistance.
  • 4.7% for those with resistance but still fully active therapy.
  • And 15.1% for those with resistance to at least one of the drugs they were prescribed.
In a multivariate analysis, the hazard ratio for virologic failure was 1.47 when the patients who had resistance but active therapy were compared with the patients who had no treatment resistance. However the difference did not reach significance.
On the other hand, the hazard ratio for virologic failure was 3.13, with a 95% confidence interval from 2.33 to 4.20, when the patients with resistance to at least one drug in their first regimen were compared with those who had no resistance, the researchers reported. The difference was significant at P<0.0001.
While all the samples were taken before treatment started, not all were tested before a regimen was prescribed, the researchers noted, something that might have accounted for some of the sub-optimal regimens.

Primary source: The Lancet Infectious Diseases
Source reference:
Wittkop L, et al "Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study" Lancet Infect Dis 2011; DOI: 10.1016/S1473-3099(11)70032-9.
 

La mitad de la población masculina podría estar infectada por el virus del papiloma humano

 Estimados colegas, les dejo esta información sobre una ITS de importancia en relación al VIH.
Saludos
Dr. Carlos Erazo


"Un estudio publicado en “The Lancet” estima que cada año se infecta con el VPH16, causante de cáncer, el 6% de los varones.

Virus del papiloma humano.
Aproximadamente el 50% de los hombres de una muestra de la población general están infectados con el virus del papiloma humano (VPH), según un estudio del Instituto de Investigación y el Centro del Cáncer H. Lee Moffitt (Estados Unidos) que se publica en la edición digital de The Lancet.
 
Cada año, el 6% de los hombres adquirirá una nueva infección por el VPH16, el virus más conocido por causar el cáncer cervical en mujeres y también tumores en varones. Además, tener múltiples parejas, mujeres u hombres, se asocia en los varones a mayores probabilidades de adquirir la infección por el VPH.
 
Sólo en Estados Unidos se estima que 32.000 casos de cáncer en hombres y mujeres en 2009 eran atribuibles a la infección por VPH. Estos cánceres fueron de cuello de útero, vagina, vulva, pene, cavidad oral, cabeza y cuello y canal anal.
 
Las verrugas anogenitales son las consecuencias más comunes de la infección por el VPH. Además de las enfermedades que el VPH causa directamente en los hombres, el virus se transmite de forma directa de hombres a mujeres y afecta en gran medida al riesgo de enfermedad en mujeres. Por este motivo, el conocimiento de la naturaleza del VPH en hombres es crucial para la salud pública y puede utilizarse para determinar si la vacunación en hombres sería rentable.
 
El estudio analizó 1.159 hombres de entre 18 y 70 años de Estados Unidos, Brasil y México que no estaban infectados por el VPH y no tenían antecedentes de cáncer. Estas personas fueron evaluadas cada 6 meses durante una media de más de dos años. La incidencia de una nueva infección genital por VPH con cualquier tipo del virus fue de 38,4 por 1.000 personas al mes.
 
Las probabilidades de cáncer causado por la infección por el VPH fue 2,4 veces mayor en los hombres que tuvieron 50 o más parejas en comparación con no tener ninguna o solamente una; y 2,6 veces mayor en aquellos que tuvieron al menos tres compañeros sexuales anales masculinos en comparación con los que no tenían parejas recientes. La media de duración de la infección por el VIH fue de 7,5 meses en cualquiera de los tipos y 12 meses en el caso del VPH16 causante de cáncer.
 
Los autores concluyen que la incidencia de la infección del VPH genital en varones fue superior y relativamente constante en todos los grupos de edad en Brasil, México y Estados Unidos. “Los resultados del estudio proporcionan datos muy necesarios sobre la incidencia y eliminación de la infección en hombres por el VPH. Estos datos son esenciales para el desarrollo de modelos de rentabilidad realistas para la vacunación masculina por VPH a nivel internacional”, concluyen los autores."

National Black HIV/AIDS

Estimados colegas esta informacion en el CDC me parece importante .
Saludos
Dr. Carlos Erazo

 http://www.cdc.gov/mmwr/pdf/wk/mm6004.pdf

February 7 is National Black HIV/AIDS Awareness Day, an observance intended to raise awareness of the disproportionate impact of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) on the black population in the United States and to encourage prevention measures, such as HIV testing. Estimates of HIV incidence for 2006 indicated that blacks had a rate of 83.7 per 100,000 population, compared with 11.5 for whites (1). Two of the three goals of the National HIV/AIDS Strategy are to reduce new HIV infections and HIV disparities (2).

In 2006, male-to-male sexual contact was associated with an estimated 63% of new HIV infections among black males (3). Among black females, high-risk heterosexual contact was associated with an estimated 83% of new infections (3). Data from CDC’s National HIV Behavioral System show that, in 2008, 59% of HIV-infected black men who have sex with men (MSM) did not know they were infected, compared with 26% of white MSM (4).

Additional information regarding National Black HIV/AIDS Awareness Day is available at http://www.cdc.gov/features/blackhivaidsawareness. Additional information regarding blacks and HIV/AIDS is available at http://www.cdc.gov/hiv/topics/aa/index.htm.
References

Occupational HIV Transmission and Prevention among Health Care Workers

Estimado colega , les dejo este FACT SHEET del CDC sobre la prevención de la transmisión del VIH en trabajadores de la salud.
Saludos
Dr. Carlos Erazo
http://www.cdc.gov/hiv/resources/factsheets/PDF/hcw.pdf

Health care workers should assume that the blood and other body fluids from all patients are potentially infectious.
They should therefore follow infection control precautions at all times.
These precautions include:

• routinely using barriers (such as gloves and/ or goggles) when anticipating contact with blood or body fluids,
• immediately washing hands and other skin surfaces after contact with blood or body fluids, and
• carefully handling and disposing of sharp instruments during and after use.

lunes, 28 de febrero de 2011

Seek and treat: HIV update 2011

Estimados colegas dejo aqui otro artículo.
Saludos
Dr. carlos Erazo

http://www.ccjm.org/content/78/2/95.full.pdf+html

Although mortality rates from human immunodeficiency virus (HIV) infection have declined dramatically in the United States, the incidence of new infections has not improved for more than a decade. The case is now strong for routine screening and early treatment of HIV infection to reduce transmission of the infection and to give patients an opportunity to live a reasonably healthy life.
Clinicians in all health care settings should routinely and matter-of-factly test their patients for HIV infection, just as they screen for other diseases.

Using Pre-Exposure Prophylaxis (PrEP) as a Prevention Tool for MSM: The Promise Comes with Challenges

Estimados colegas, este es un nuevo cometario sobre la implementación del PREP , en USA.
Saludos
Dr. Carlos Erazo

http://blog.aids.gov/2011/02/using-pre-exposure-prophylaxis-prep-as-a-prevention-tool-for-msm-the-promise-comes-with-challenge-.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+aids%2Fgov+%28Blog.AIDS.gov%29

By Ronald Valdiserri, M.D., M.P.H, Deputy Assistant Secretary for Health, Infectious Diseases, U.S. Department of Health and Human Services
CAPTION
Dr. Ronald Valdiserri
On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention studies, health care providers caring for men-who-have-sex-with-men (MSM), state and local health department program directors, MSM community advocates, policy experts, and federal officials.
The meeting began with a detailed review of the iPrEx study, which included nearly 2,500 participants from Peru, Ecuador, Brazil, Thailand, South Africa, and the United States. Participants were MSM engaging in high-risk sex with other men—including a small number of transgender women who reported high-risk sex with men. The study findings, released in November 2010, showed that sexually active MSM who took a once-daily pill containing 2 anti-HIV drugs were 44% less likely to become infected with HIV, compared with participants who took a placebo.
Because iPrEx was a “blinded” study, participants did not know if they were receiving active drugs or placebos (inactive drugs). As such, all study participants received intensive risk-reduction counseling. Along with this counseling, all study participants also received monthly HIV testing, condom provision, and treatment for other acquired sexually transmitted diseases.
When these results were summarized at the Saturday meeting in Boston, the audience was reminded that the level of protection experienced by study participants who received the active drug varied widely, depending upon how consistently they took their daily pills. For those who took the daily drug at least 90% of the time, HIV risk was reduced by 73%. Others, who took the drug less frequently, had only a 21% reduction in HIV risk. Given this finding, a significant theme of our discussion in Boston was the critical role that adherence counseling must play in any future efforts to develop and implement PrEP programs for MSM.
The U.S. Public Health Service is currently at work on guidelines for PrEP use among MSM. In the meantime, CDC has released interim guidance, as well as a fact sheet on Pre-Exposure Prophylaxis for HIV Prevention (PDF). But, as our meeting in Boston highlighted, there are many critical questions that must be answered before we can move this important prevention research finding from the pages of a scientific journal and into the day-to-day lives of MSM who are at high, ongoing risk for HIV infection. Several of the major questions raised by participants were:
  • Among the diverse communities of MSM in the U.S., what subset of men would be the most appropriate candidates for this new prevention tool?
  • Given the disproportionate burden of HIV infection among MSM of color—many of whom also live at or near the poverty level—how will daily drug treatments be financed?
  • In the real world of competing needs and resource constraints, how should PrEP programs for MSM be combined with other prevention approaches for MSM to result in the greatest pay-off in terms of decreasing new HIV infections?
  • How do we build the needed capacity among medical providers, health departments, and community-based organizations so that PrEP can be implemented as part of a comprehensive package of HIV prevention services for MSM at risk for HIV?
  • Could PrEP serve as a “gateway” into other equally effective—and perhaps less costly—prevention approaches for MSM?
While everyone at the Boston meeting recognized the promise of this new tool, there was a general consensus that PrEP is not a “magic bullet” and that it should not be viewed as the sole approach to reducing new HIV infections among MSM.
Moving forward with discussions about how to implement PrEP as a new prevention strategy for MSM, let’s keep in mind the necessity of supporting combined biomedical, behavioral, and structural approaches—all of which are called for in the National HIV/AIDS Strategy. Given the ongoing burden of new HIV infections among MSM communities in the United States, we are obliged to carefully examine our current approaches and, when called for, make changes in where and how we deliver our HIV prevention services.

viernes, 25 de febrero de 2011

Postpartum changes in plasma viral load and CD4 percentage among HIV-infected women from Latin American and Caribbean countries: the NISDI Perinatal Study

Saludos
Dr. Carlos Erazo
http://www.scielo.br/pdf/mioc/v106n1/16.pdf


The goal of this study was to evaluate changes in plasma human immunodeficiency virus (HIV) RNA concentration [viral load (VL)] and CD4+  percentage (CD4%) during 6-12 weeks postpartum (PP) among HIV-infected women and to assess differences according to the reason for receipt of antiretrovirals (ARVs) during pregnancy [prophylaxis (PR) vs. treatment (TR)]. Data from a prospective cohort of HIV-infected pregnant women (National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study) were analyzed. Women experiencing their first pregnancy who received ARVs for PR (started during pregnancy, stopped PP) or for TR (initiated prior to pregnancy and/or continued PP) were included and were followed PP. Increases in plasma VL  (≥ 0.5 log 10 ) and decreases in CD4% (≥ 20% relative decrease in CD4%) between hospital discharge (HD) and PP were assessed. Of the 1,229 women enrolled, 1,119 met the inclusion criteria (PR: 601; TR: 518). At enrollment, 87%  were asymptomatic. The median CD4% values were: HD [34% (PR); 25% (TR)] and PP [29% (PR); 24% (TR)]. The  VL increases were 60% (PR) and 19% (TR) (p < 0.0001). The CD4% decreases were 36% (PR) and 18% (TR) (p < 0.0001). Women receiving PR were more likely to exhibit an increase in VL [adjusted odds ratio (AOR) 7.7 (95%  CI: 5.5-10.9) and a CD4% decrease (AOR 2.3; 95% CI: 1.6-3.2). Women receiving PR are more likely to have VL increases and CD4% decreases compared to those receiving TR. The clinical implications of these VL and CD4% changes remain to be explored. 

Vertical transmission of HIV-1 in the western region of the State of São Paulo

Saludos colegas
Dr. Carlos Erazo

http://www.scielo.br/pdf/rsbmt/v44n1/02.pdf

ABSTRACT
Introduction: This study aimed to determine the prevalence of vertical HIV-1 transmission  in the western region of the State of São Paulo, Brazil. Methods: The study analyzed the medical records of HIV-1-infected mothers and infant pairs living in the municipalities of São Paulo Regional Health Departments DRS II (Araçatuba) and DRS XI (Presidente Prudente). From March 2001 to March 2006, blood samples were collected and referred to the Molecular Biology Unit of the Adolfo Lutz Institute (ALI), Presidente Prudente. HIV-1-RNA viral load was determined by bDNA assay. Results: The number of births (109/217, 50.2%) and vertical HIV-1 transmissions (6/109, 5.5%) that occurred in DRS II was similar to births (108/217, 49.8%) and vertical transmissions (7/108, 6.5%) in DRS XI (p > 0.05). Although 80% (4/5) of the infected children were male in DRS II, while in DRS XI, 75% (6/8) were female, no differences between sex regarding infected and noninfected children in the regions of Araçatuba and Presidente Prudente were verified. The overall vertical HIV-1 transmission rate was 6%. No consistent reduction in the prevalence of vertical HIV-1 transmission occurred over the years. About 20% of mothers did not know the HIV-1 status 
of their newborns eight months after delivery. Conclusions: In the present study, MTCT prevalence rates were about 70% higher than those previously determined in the State of São Paulo, with no reduction throughout the period. Furthermore, a significant number of mothers did not know the HIV-status of their newborns eight months after delivery

Acceptability of donated breast milk in a resource limited South African setting

Estimados colegas, continuo colocando información en este sitio donde podemos continuar informandonos de lo que existe en cuanto a VIH.
Saludos 
Dr. Carlos Erazo
Background 
The importance of breast milk for infants’ growth, development and overall health is widely recognized. In situations where women are not able to provide their infants with sufficient amounts of their own breast milk, donor breast milk is the next preferred option. Although there is considerable research on the safety and scientific aspects of donor milk, and the motivations and experiences of donors, there is limited research addressing the attitudes and experiences of the women and families whose infants receive this milk. This study therefore examined attitudes towards donated breast milk among mothers, families and healthcare providers of potential recipient infants.  
Methods 
The study was conducted at a public hospital and nearby clinic in Durban, South Africa. The qualitative data was derived from eight focus group discussions which included four groups with mothers; one with male partners; and one with grandmothers, investigating attitudes towards receiving donated breast milk for infants. There was also one group each with nurses and doctors about their attitudes towards donated breast milk and its use in the hospital. The focus groups were conducted in September and October 2009 and each group had between four and eleven participants, leading to a total of 48 participants. 
Results 
Although breast milk was seen as important to child health there were concerns about undermining of breast milk because of concerns about HIV and marketing and promotion of formula milks. In addition there were concerns about the safety of donor breast milk and discomfort about using another mother’s milk. Participants believed 3 that education on the importance of breast milk and transparency on the processes 
involved in sourcing and preparing donor milk would improve the acceptability.  
Conclusions 
This study has shown that there are obstacles to the acceptability of donor milk, mainly stemming from lack of awareness/familiarity with the processes around donor breast milk and that these could be readily addressed through education. Even the more psychological concerns would also likely be reduced over time as these educational efforts progress. With government and health care worker endorsement and commitment, breast milk donation could have a promising role in improving child health.

The STEP Study Provides a Hint That Vaccine Induction of the Right CD8 1 T Cell Responses Can Facilitate Immune Control of HIV

Estimados colegas , este es un estudio interesante vale la pena leerlo.
Saludos 
Dr. Carlos Erazo

The STEP study was a large, randomized, placebo-controlled, test-of-concept vaccine trial using an Ad5 vector expressing human immunodeficiency virus (HIV)–1 Gag, Pol, and Nef designed to induce T cell immunity to HIV-1. This trial was stopped and unblinded in 2007 after an interim analysis showed that the vaccine did not achieve efficacy for the 2 primary study end points, HIV-1 acquisition and plasma HIV-1 RNA levels 3 months after diagnosis of HIV-1 infection, and suggested that vaccinated individuals with high preexisting antibody titers against Ad5 might be at a higher risk of acquiring HIV-1 infection [1–2]. These results initiated reconsideration in the HIV-1 research field of the role of T cells in protection from HIV-1 infection and disease progression.


http://jid.oxfordjournals.org/content/203/6/753.full.pdf+html

“One Teabag Is Better than Four”: Participants Response to the Discontinuation of 2% PRO2000/5 Microbicide Gel in KwaZulu-Natal, South Africa

Estimados colegas, otro artículo.

Saludos 
Dr. Carlos Erazo

http://www.plosone.org/article/info:doi/10.1371/journal.pone.0014577

Introduction

The Microbicides Development Programme evaluated the safety and effectiveness of 0.5% and 2% PRO2000/5 microbicide gels in reducing the risk of vaginally acquired HIV. In February 2008 the Independent Data Monitoring Committee recommended that evaluation of 2% PRO2000/5 gel be discontinued due to futility. The Africa Centre site systematically collected participant responses to this discontinuation.

Methods

Clinic and field staff completed field reports using ethnographic participant observation techniques. In-depth-interviews and focus group discussions were conducted with participants discontinued from 2% gel. A total of 72 field reports, 12 in-depth-interviews and 3 focus groups with 250 women were completed for this analysis. Retention of discontinued participants was also analysed. Qualitative data was analysed using NVivo 2 and quantitative data using STATA 10.0.

Results

Participants responded initially with fear that discontinuation was due to harm, followed by acceptance after effective messaging, and finally with disappointment. Participants reported that their initial fear was exacerbated by being contacted and advised to visit the clinic for information about the closure. Operational changes were subsequently made to the contact procedures. By incorporating feedback from participants, messages were continuously revised to ensure that information was comprehensible and misconceptions were addressed quickly thereby enabling participants to accept the discontinuation. Participants were disappointed that 2% PRO2000/5 was being excluded as a HIV prevention option, but also that they would no longer have access to gel that improved their sexual relationships with their partners and assisted condom negotiations. In total 238 women were discontinued from gel and 185 (78%) went on to complete their scheduled follow-up period.

Discussion

The use of qualitative social science techniques allowed the site team to amend operational procedures and messaging throughout the discontinuation period. This proved instrumental in ensuring that the discontinuation was successfully completed in a manner that was both understandable and acceptable to participants.

Associação entre violência por parceiro íntimo contra a mulher e infecção por HIV

Estimados colegas , otro artículo interesante.
Saludos
Dr.Carlos Erazo

RESUMO
OBJETIVO: Analisar a associação entre a violência por parceiro íntimo contra mulheres e a infecção ou suspeita de infecção pelo vírus da imunodefi ciência humana (HIV).
MÉTODOS: Estudo transversal com base em dados de questionários aplicados face-a-face e de prontuários médicos de 2.780 mulheres de 15 a 49 anos, atendidas em unidades do sistema único de saúde da Grande São Paulo, SP, em 2001-2002. As mulheres foram categorizadas em: usuárias em tratamento 
por serem “soropositivas para o HIV”, com “suspeita de HIV” e aquelas que procuraram os serviços por outros motivos. A violência por parceiro íntimo contra mulheres na vida foi categorizada por gravidade e recorrência dos episódios de violência. A associação com o desfecho foi testada pelo modelo de Poisson com variância robusta e ajustada por variáveis sociodemográfi cas, sexuais e reprodutivas.
RESULTADOS: A prevalência de violência foi de 59,8%. Sofrer violência reiterada e grave apresentou maior associação de infecção confi rmada pelo HIV (RP = 1,91). A violência independente da gravidade e da recorrência dos episódios apresentou maior associação para a suspeita de infecção por HIV (RP = 1,29). 
CONCLUSÕES: A violência por parceiro íntimo contra mulheres tem papel relevante nas situações de suspeita e confi rmação da infecção pelo HIV, sendo essencial incluir sua detecção, controle e prevenção como parte da atenção integral à saúde das mulheres.

HCV co-infection in HIV positive population in British Columbia, Canada

Estimados colegas este es otro artículo interesante.
Saludos
Dr. Carlos Erazo
Abstract
Background: As HIV and hepatitis C (HCV) share some modes of transmission co-infection is not uncommon. This study used a population-based sample of HIV and HCV tested individuals to determine the prevalence of HIV/HCV coinfection, the sequence of virus diagnoses, and demographic and associated risk factors. Methods: Positive cases of HIV were linked to the combined laboratory database (of negative and positive HCV antibody results) and HCV reported cases in British Columbia (BC).
Results: Of 4,598 HIV cases with personal identifiers, 3,219 (70%) were linked to the combined HCV database, 1,700  (53%) of these were anti-HCV positive. HCV was diagnosed first in 52% of co-infected cases (median time to HIV identification 3 1/2 years). HIV and HCV was diagnosed within a two week window in 26% of cases. Among individuals who were diagnosed with HIV infection at baseline, subsequent diagnoses of HCV infection was independently associated with: i) intravenous drug use (IDU) in males and females, Hazard Ratio (HR) = 6.64 (95% CI: 4.86-9.07) and 9.76 (95% CI: 5.76-16.54) respectively; ii) reported Aboriginal ethnicity in females HR = 2.09 (95% CI: 1.34-3.27) and iii) males not identified as men-who-have-sex-with-men (MSM), HR = 2.99 (95% CI: 2.09-4.27). Identification of HCV first compared to HIV first was independently associated with IDU in males and females OR = 2.83 (95% CI: 1.84-4.37) and 2.25 (95% CI: 1.15-4.39) respectively, but not Aboriginal ethnicity or MSM. HIV was identified first in 22%, with median time to HCV identification of 15 months; Conclusion: The ability to link BC public health and laboratory HIV and HCV information provided a unique opportunity to explore demographic and risk factors associated with HIV/HCV co-infection. Over half of persons with HIV infection who were tested for HCV were anti-HCV positive; half of these had HCV diagnosed first with HIV identification a median 3.5 years later. This highlights the importance of public health follow-up and harm reduction measures for people identified with HCV to prevent subsequent HIV infection.


Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial

Estimados colegas, aqui un artículo interesante en cuanto a la Transmisión materno infantil.
Saludos
Dr. Carlos Erazo


http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-3WBNMWW-7&_user=10&_coverDate=03/06/1999&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_searchStrId=1656570567&_rerunOrigin=scholar.google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=cd7a81cfe38a07a91f1e78f5db2d535c&searchtype=a

DEPOSITO DE INFORMACION SOBRE EL ESTUDIO HSH

http://sites.google.com/site/ecuadorencuestahsh2010/home

Introduction to Biostatistics

Otro curso gratis para poder ingresar lea el silabus que esta en el siguiente link>

http://www.ccghe.jhmi.edu/assets/Biostats_Syllabus2.pdf

Saludos
Dr. Carlos Erazo

Introduction to Research Ethics Distance Education Online Course http://ccghe.org

Introduction to Research Ethics
Distance Education Online Course
http://ccghe.org

Estimados Colegas este curso on line es gratuito, les adjunto el link para que se enteren de este curso y participen los que esten interesados.

Saludos

Dr, Carlos Erazo
http://www.ccghe.jhmi.edu/assets/Research_Ethics_Online_Syllabus.pdf

miércoles, 23 de febrero de 2011

Resolución sobre la actualización de la Clasificación Internacional Uniforme de Ocupaciones

Estimados colegas, este es el documento  donde se coloca la lista internacional de ocupaciones respaldados por la OIT(Organización Internacional del Trabajo) .
Esta clasificación será la que se utilizará en el nuevo formato de notificación de casos SIDA.

Les dejo el Link para que puedan bajar el pdf de este documento.
Saludos
Dr. Carlos Erazo


http://www.ilo.org/public/spanish/bureau/stat/isco/docs/resol08.pdf

martes, 22 de febrero de 2011

A Surprising Prevention Success: Why Did the HIV Epidemic Decline in Zimbabwe?

 Estimados colegas, miren este artículo intersante realizado en Zimbawe.
Saludos
Dr. Carlos Erazo

http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000414

* Existe un creciente reconocimiento de que la prevención primaria, incluyendo el cambio de comportamiento, debe ser central en la lucha contra el VIH / SIDA. Los éxitos anteriores en Tailandia y Uganda no puede ser totalmente relevantes para los países afectados del sur de África.
     * Se realizó una síntesis amplia multi-disciplinario de los datos disponibles sobre las causas de la notable disminución de VIH que se ha producido en Zimbabwe (29% de prevalencia de adultos estimada en 1997 a 16% en 2007), en el contexto de graves sociales, políticos, y económico interrupción.
     * Los cambios de comportamiento asociados con la reducción del VIH, principalmente reducciones en las relaciones sexuales extramaritales, comercial e informal, y las reducciones asociadas en los países socios de concurrencia-parecen haber sido estimulada principalmente por una mayor conciencia de las muertes por SIDA y en segundo lugar por el deterioro económico del país. Estos cambios fueron ayudados probablemente por los programas de prevención de la utilización de los medios de comunicación de masas y basados en la iglesia, el lugar de trabajo y otras actividades de comunicación interpersonal.
     * El enfoque en la reducción de socios, además de promover el uso de preservativos para el sexo casual y otros enfoques basados en la evidencia, es crucial para el desarrollo de programas de prevención más eficaz, especialmente en las regiones con epidemias generalizadas de VIH.